TrialThe Lancet. Oncology2009

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.

Ezra E W Cohen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.